Fundraising Fox

Anto Biosciences

YC F25

San Francisco, US · Founded 2025 · 4 employees · 3 known investors

Find your way into Anto Biosciences

1,728 people in our graph share verified history with the Anto Biosciences team — schools, employers, funds. One of them is your warm intro.

Tobi Cokerunlockedknows David de Gruijl · together at Stealth (overlapped)
×2knows the team · via Massachusetts Institute of Technology
×5knows the team · via Broad Institute of MIT and Harvard
knows the team · via Harvard University
×3knows the team · via The Chinese University of Hong Kong

Anto is an AI research lab developing foundation models for microbial communities to enable precision medicine by computationally modeling how the microbiome affects individual drug response. The company serves pharmaceutical and clinical research by combining AI with genomic and microbiome data.

Also known as Anto

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesArtificial IntelligenceGenerative AIGenomicsDrug discoveryUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (F25)

Anto Biosciences was founded in 2025 by Arvid E. Gollwitzer and David de Gruijl.

AEArvid E. Gollwitzer
Arvid E. Gollwitzerin𝕏FounderArvid E. Gollwitzer is a researcher with experience at the Broad Institute, Harvard, and MIT, and has held a lecturer position at ETH Zurich. He is the founder of Anto Biosciences.
DDDavid de Gruijl
David de Gruijlin𝕏FounderDavid de Gruijl is a co-founder of Anto Biosciences with prior experience at Janssen Pharmaceuticals and research affiliations with ETH Zurich and the Gastroenterology Department at Brigham and Women's Hospital, Harvard Medical School.

Investors · 3

RRE VenturesNew York · $5M – $15M
Y CombinatorSan Francisco · $500K
Tekedia CapitalreportedLagos · $1K

The YC application· Fall 2025 batch

Anto Biosciences - YC F25 - Launch Video

Arvid E. Gollwitzer

Competitors · 3

by search overlap
Octant Bio14 shared keywordsOctant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases. Using synthetic biology, high-throughput chemistry, and AI/ML, the company's Navigator platform studies how target proteins interact within living human cells to enable drug discovery for rare diseases and oncology.
Intuitive Biosciences8 shared keywordsIntuitive Bio develops Colony Surveillance Assays (CSA), diagnostic kits for screening laboratory animal colonies for exposure to specific pathogens. The kits are designed for research institutions and breeding facilities requiring pathogen-free colony verification.
Engage Bio7 shared keywordsEngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.

Companies competing with Anto Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Tekedia Capital Invests in Anto Biosciences, Pioneering New AI Models for Drug Development - Tekediatekedia.com · Jun 2026Anto Biosciences: A Foundation Model for Microbial Communitiesycombinator.com · Nov 2025Anto Biosciences Funding: $1M | Complete Analysis | Extruct AIextruct.ai

Frequently asked questions

What does Anto Biosciences do?
Anto is an AI research lab developing foundation models for microbial communities to enable precision medicine by computationally modeling how the microbiome affects individual drug response. The company serves pharmaceutical and clinical research by combining AI with genomic and microbiome data.
Who founded Anto Biosciences?
Anto Biosciences was founded by Arvid E. Gollwitzer, David de Gruijl in 2025.
Who are Anto Biosciences's investors?
Anto Biosciences's investors include RRE Ventures, Y Combinator, Tekedia Capital.
Where is Anto Biosciences headquartered?
Anto Biosciences is headquartered in San Francisco, US.